NorthWest Biotherapeutics Inc (NWBO)

[GoodGuyBill]

I don't know what you mean by "commissioned vs recommended". I don't think the phrasing matters. I use the phrase, "approved, though on a case-by-case IFR". Here's the gist, imho: DCVax-L was approved, period. This approval, at the moment, requires an IFR. But for those patients who (1) are diagnosed with "covered" cancers (likely expanded to all tumor-based cancers), (2) have an IFR submitted by their medical team and, (2) that IFR is successful, DCVax-L is "APPROVED". So, no matter the phrasing, DCVax-L is validated by NHS, a top tier regulatory agency, as safe, efficacious and of significant value. If NHS didn't see DCVax-L in this light, it wouldn't be on the HCD list, available to anyone in any circumstance. NHS damn sure wouldn't fund it in any way.

Now, we have the naysayers making light of this "approval", saying it is limited and of little or no value, that NWBO will never make enough revenues to cover expenses or that the addition of DCVax-l to the HCD list means nothing. They are wrong. What is likely happening here is that NHS has looked at all of DCVax-L's data and concluded that they need to get this treatment to its citizenry NOW. So, the NHS is using IFR funding to jump-start DCVax-L accessibility. It's as if NHS said to NICE, " DCVax-L is a godsend. We need to make this available now. I know you have to go through your process before our citizenry can have full access to DCVax-L but we are going to place DCVax-L on the HCD list to make this available NOW while you work through your process." Were you aware that NHS added significant additional funding to cancer treatment in 2024? Now you know why.

Naysayers with any credibility/integrity can never again say the trial was flawed, DCVax-L will never get approval or is no better than grapefruit juice, etc, etc, etc.